Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects
with relapsed or refractory Multiple Myeloma.
The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics
of AEVI-007.